{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T05:02:40Z","timestamp":1784955760488,"version":"3.55.0"},"reference-count":36,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Dual antiplatelet therapy (DAPT) with acetylsalicylic acid (hereafter referred to as ASA) and ticagrelor is the standard of care for secondary prevention for atherothrombotic events, particularly in patients with noncardioembolic cerebrovascular disease or coronary artery disease. However, prolonged DAPT requires multiple daily tablets, which can compromise adherence; a fixed\u2010dose combination could reduce pill burden and improve treatment persistence. This study evaluated the comparative bioavailability of a fixed\u2010dose combination (FDC) capsule of ticagrelor 90 mg\/ASA 100 mg (test) versus the concomitant administration of ticagrelor 90 mg tablet plus ASA 100 mg tablet (reference) under fasting conditions in healthy Mexican volunteers. We applied a randomized, open\u2010label, two\u2010period crossover, single\u2010dose design with a 7\u2010day washout and quantified plasma concentrations by liquid chromatography\u2010tandem mass spectrometry. Twenty\u2010four subjects were enrolled. Geometric mean ratios (90% confidence intervals) for ticagrelor maximum plasma concentration and area under the plasma concentration\u2010time curve from 0 to 48 h, were 111.5% (102.3\u2013121.5), and 100.3% (93.4\u2013107.7); for salicylic acid, 95.4% (90.1\u2013100.9), and 101.5% (96.7\u2013106.5). All 90% confidence intervals fell within the predefined 80\u2013125% range, and both formulations were well tolerated. These findings support the FDC as an alternative that may simplify long\u2010term DAPT for the secondary prevention of atherothrombotic events.<\/jats:p>","DOI":"10.1002\/cpdd.70084","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:28:44Z","timestamp":1784554124000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative bioavailability of a novel fixed\u2010dose combination of ticagrelor and acetylsalicylic acid"],"prefix":"10.1002","volume":"15","author":[{"given":"Susana","family":"Tera\u2010Ponce","sequence":"first","affiliation":[{"name":"Department of Pharmacology Faculty of Medicine National Autonomous University of Mexico (UNAM)  Mexico City Mexico"},{"name":"Unidad Cl\u00ednica Farmacol\u00f3gica Bioemagno S. A. de C. V  Mexico City Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perla E.","family":"Casta\u00f1eda\u2010Tera","sequence":"additional","affiliation":[{"name":"Unidad Cl\u00ednica Farmacol\u00f3gica Bioemagno S. A. de C. V  Mexico City Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elva J.","family":"Garc\u00eda\u2010Real","sequence":"additional","affiliation":[{"name":"Unidad Cl\u00ednica Farmacol\u00f3gica Bioemagno S. A. de C. V  Mexico City Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"\u00c1vila\u2010Garc\u00eda","sequence":"additional","affiliation":[{"name":"Bioanalit Laboratorios S.A. de C.V  Mexico City Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin F.","family":"Rios\u2010Brito","sequence":"additional","affiliation":[{"name":"Research and Development Department Laboratorios Silanes S.A. de C.V.  Mexico City Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Lugo\u2010S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Research and Development Department Laboratorios Silanes S.A. de C.V.  Mexico City Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Sandoval\u2010Colin","sequence":"additional","affiliation":[{"name":"Research and Development Department Laboratorios Silanes S.A. de C.V.  Mexico City Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola M.","family":"Medina\u2010C\u00e1rdenas","sequence":"additional","affiliation":[{"name":"Research and Development Department Laboratorios Silanes S.A. de C.V.  Mexico City Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Gonz\u00e1lez\u2010Canudas","sequence":"additional","affiliation":[{"name":"Research and Development Department Laboratorios Silanes S.A. de C.V.  Mexico City Mexico"},{"name":"Mexican Social Security Institute (IMSS) Centro M\u00e9dico Nacional Siglo XXI  Mexico City Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2016.111"},{"issue":"1","key":"e_1_2_8_3_1","first-page":"34","article-title":"Acute Coronary Syndrome: Diagnosis and Initial Management","volume":"109","author":"Nohria R","year":"2024","journal-title":"Am Fam Physician"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0b013e318296aeca"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0118-8"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30499-X"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/17474930241308142"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.07.025"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature13288"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904327"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000200355"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1477"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61274-3"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGENETICS.110.958561"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2024.2386368"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500857"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916870"},{"issue":"13","key":"e_1_2_8_18_1","first-page":"e771","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"151","author":"Rao SV","year":"2025","journal-title":"Circulation"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2006.08.033"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.109.139816"},{"key":"e_1_2_8_21_1","volume-title":"Guideline on Clinical Development of Fixed Combination Medicinal Products. EMA\/CHMP\/158268\/2017","year":"2017"},{"key":"e_1_2_8_22_1","volume-title":"Bioavailability and Bioequivalence Studies for Orally Administered Drug Products: Guidance for Industry","year":"2003"},{"key":"e_1_2_8_23_1","volume-title":"NOM\u2010177\u2010SSA1\u20102013. Mexican Official Standard. Tests for Pharmaceutical Equivalence, Interchangeability of Medicines, and Requirements for Authorized Third Parties","year":"2013"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.3109\/09537104.2012.748185"},{"key":"e_1_2_8_25_1","volume-title":"Statistical Approaches to Establishing Bioequivalence: Guidance for Industry","year":"2026"},{"key":"e_1_2_8_26_1","unstructured":"ICH Harmonised Guideline M13A: Bioequivalence for Immediate\u2010Release Solid Oral Dosage Forms.International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use;2024."},{"key":"e_1_2_8_27_1","volume-title":"Phoenix WinNonlin Version 8.4 User Guide","year":"2021"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.04.002"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.2217\/14750708.2.3.465"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/life13071580"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16020178"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.25259\/AJPPS_2024_008"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1471"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.2515\/therapie:2005021"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01486-9"},{"key":"e_1_2_8_36_1","volume-title":"NDA Approval Letter: Brilinta (Ticagrelor) 90 mg Tablets. NDA 022433","year":"2011"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab484"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.70084","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpdd.70084","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.70084","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T04:41:30Z","timestamp":1784954490000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.70084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1002\/cpdd.70084"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.70084","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2026-05-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70084"}}